Article

AcrySof toric IOL offers spectacle independence

The AcrySof toric intraocular lens (IOL) (Alcon) offers greater spectacle independence than the monofocal AcrySof SA60AT single-piece IOL (Alcon).

The AcrySof toric intraocular lens (IOL) (Alcon) offers greater spectacle independence than the monofocal AcrySof SA60AT single-piece IOL (Alcon), according to Paul Ernest from Jackson, USA.

Dr Ernest enrolled 480 patients and randomized them to receive either the control lens, AcrySof SA60AT single piece IOL (n=237), or the AcrySof toric IOL (n=243). Each patient had at least 0.75 D of regular astigmatism and age-related cataracts in one or both eyes.

The toric IOL patients reported a significantly greater rate of spectacle independence than controls (p<0.0001). Compared with controls, the percentage of toric patients achieving an uncorrected distance visual acuity (UDCVA) of 20/20 or better (19.4% versus 40.7%, respectively) or 20/25 or better (41.4% versus 63.7%, respectively) was significant (p<0.0001).

The comparison of the lenses demonstrates that the AcrySof toric IOL offers a much greater level of spectacle independence than its monofocal counterpart.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.